Drugs / VSL#3
VSL#3
Trials 45 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT03682094 | Aug 2018 → Jan 2020 | — | University of Wisconsin, Madison | Completed | No outcome recorded |
| Phase 0 | NCT03574051 | May 2018 → May 2020 | — | First Affiliated Hospital of Harbin Medical University | Unknown | No outcome recorded |
| Phase 17 trials | ||||||
| Phase 1 | NCT06297213 | Jun 2026 → Aug 2028 expected | Sjogren syndrome | Rise Therapeutics LLC | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07234227 | Jun 2026 → Nov 2027 expected | urinary system disorder | Duke University | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT05961592 | Oct 2023 → Nov 2026 expected | rheumatoid arthritis | Rise Therapeutics LLC | Recruiting | No outcome recorded |
| Phase 1 | NCT04165551 | Oct 2019 → Sep 2020 | group B streptococcal infection | Biosearch S.A. | Unknown | No outcome recorded |
| Phase 1 | NCT02286999 | Oct 2015 → Jan 2018 | atopic eczema, food allergy | Emanual Maverakis, MD | Withdrawn | No outcome recorded |
| Phase 1 | NCT00971711 | Sep 2009 → Dec 2013 | irritable bowel syndrome | Baylor College of Medicine | Completed | No outcome recorded |
| Phase 1 | NCT00099723 | Oct 2004 → Dec 2005 | fatty liver disease | VSL Pharmaceuticals | Terminated | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT04119011 | Oct 2019 → Mar 2020 | primary dysmenorrhea | National University of Malaysia | Completed | No outcome recorded |
| Phase 1/2 | NCT03511365 | May → Dec 2018 | NAFLD1 | Northwell Health | Terminated | No outcome recorded |
| Phase 1/2 | NCT03399903 | May 2017 → Mar 2019 | HIV infectious disease, colitis | AIDS Healthcare Foundation | Completed | No outcome recorded |
| Phase 1/2 | NCT01032941 | Dec 2009 → Jun 2011 | portal hypertension | University of Alberta | Completed | No outcome recorded |
| Phase 211 trials | ||||||
| Phase 2 | NCT06949800 | Sep 2026 → May 2027 expected | human papillomavirus-related squamous cell carcinoma, squamous cell intraepithelial neoplasia | University of California, San Francisco | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07413744 | Aug 2026 → Mar 2029 expected | Alzheimer disease | University of Wisconsin, Madison | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07189390 | May 2026 → May 2029 expected | immune dysregulation, neurodevelopmental defects, and colitis | South Australian Health and Medical Research Institute | Recruiting | No outcome recorded |
| Phase 2 | NCT06102213 | Sep 2023 → Aug 2024 | hematopoietic and lymphoid cell neoplasm | Prolacta Bioscience | Terminated | No outcome recorded |
| Phase 2 | NCT05608928 | Dec 2022 → May 2023 | — | Tropical Gastroenterology & Nutrition Group (TROPGAN) | Unknown | No outcome recorded |
| Phase 2 | NCT03386643 | Nov 2017 → Apr 2018 | lichen planus, oral | University of Sao Paulo | Completed | No outcome recorded |
| Phase 2 | NCT03165747 | Oct 2017 → Mar 2019 | postmenopausal osteoporosis | Emory University | Terminated | No outcome recorded |
| Phase 2 | NCT01701297 | Feb 2012 → Oct 2014 | cirrhosis of liver | Nottingham University Hospitals NHS Trust | Terminated | No outcome recorded |
| Phase 2 | NCT01465802 | Dec 2011 → May 2015 | non-small cell lung carcinoma | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT00630838 | Sep 2006 → Sep 2010 | Hirschsprung disease | University of Michigan | Completed | No outcome recorded |
| Phase 2 | NCT00319007 | Apr → Dec 2006 | classic or attenuated familial adenomatous polyposis | Radboud University Medical Center | Unknown | No outcome recorded |
| Phase 2/35 trials | ||||||
| Phase 2/3 | NCT03829358 | Feb → Jul 2018 | constipation disorder | Faculty of Medicine, University of Indonesia | Completed | No outcome recorded |
| Phase 2/3 | NCT02752594 | Apr 2015 | dental caries | Sharda University | Completed | No outcome recorded |
| Phase 2/3 | NCT03078530 | Sep 2013 → May 2018 | persian gulf syndrome | Ashok Tuteja | Unknown | No outcome recorded |
| Phase 2/3 | NCT01110447 | Apr 2010 → Mar 2013 | hepatic encephalopathy | CD Pharma India Pvt. Ltd. | Completed | No outcome recorded |
| Phase 2/3 | NCT01008293 | Oct 2009 → Jun 2012 | hepatic encephalopathy, liver disorder | CD Pharma India Pvt. Ltd. | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT02545413 | May 2016 → Jun 2017 | irritable bowel syndrome | Next Gen Pharma India Pvt. Ltd. | Withdrawn | No outcome recorded |
| Phase 3 | NCT00175292 | Dec 2003 → ? | Crohn disease | University of Alberta | Completed | No outcome recorded |
| Phase 3 | NCT01134692 | — | cirrhosis of liver, esophageal varices | Govind Ballabh Pant Hospital | Unknown | No outcome recorded |
| Phase 45 trials | ||||||
| Phase 4 | NCT01765998 | Feb 2013 → Feb 2014 | Crohn disease | The Baruch Padeh Medical Center, Poriya | Unknown | No outcome recorded |
| Phase 4 | NCT01638208 | Aug → Dec 2012 | irritable bowel syndrome | Asian Institute of Gastroenterology, India | Unknown | No outcome recorded |
| Phase 4 | NCT01479660 | Mar 2011 → Oct 2014 | ulcerative colitis | Post Graduate Institute of Medical Education and Research, Chandigarh | Unknown | No outcome recorded |
| Phase 4 | NCT00418340 | Dec 2007 → ? | irritable bowel syndrome | London North West Healthcare NHS Trust | Unknown | No outcome recorded |
| Phase 4 | NCT00114465 | Jun 2005 → Dec 2008 | Crohn disease | Orphan Australia | Completed | No outcome recorded |
| Phase not applicable8 trials | ||||||
| — | NCT07331987 | Jun → Dec 2026 expected | mixed anxiety and depressive disorder | Moon (Guangzhou) Biotechnology Co., Ltd. | Recruiting | No outcome recorded |
| — | NCT05548361 | Apr 2022 → Dec 2024 | periodontitis | Cukurova University | Completed | No outcome recorded |
| — | NCT05007470 | Jan 2022 → Jun 2025 overdue | alcoholic liver disease | University of California, Los Angeles | Active not recruiting | No outcome recorded |
| — | NCT02736994 | Apr → Sep 2014 | — | Universitaire Ziekenhuizen KU Leuven | Completed | No outcome recorded |
| — | NCT01196481 | Dec 2012 → Aug 2015 | cirrhosis of liver | Institute of Liver and Biliary Sciences, India | Completed | No outcome recorded |
| — | NCT01273012 | Apr 2010 → Aug 2011 | acute diarrhea | Phramongkutklao College of Medicine and Hospital | Unknown | No outcome recorded |
| — | NCT00179582 | Jan 2005 → Jan 2006 | irritable bowel syndrome | Beth Israel Deaconess Medical Center | Terminated | No outcome recorded |
| — | NCT00159523 | Dec 2003 → Sep 2007 | asthma, atopic eczema, perennial allergic rhinitis | Norwegian University of Science and Technology | Completed | No outcome recorded |
Also used as a comparator or background therapy in 13 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT01635192 Comparator | Dec 2011 → Jul 2013 | — | Göteborg University | Completed | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT00932841 Comparator | Jan 2008 → Aug 2011 | irritable bowel syndrome | Dayton Children's Hospital | Terminated | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05254249 Comparator | Feb → Aug 2022 | psoriasis | Dr. Soetomo General Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT00852124 Comparator | Feb 2007 → Jan 2013 | asthma | University of Maryland, Baltimore | Terminated | No outcome recorded |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT02011542 Comparator | Sep 2013 → Jul 2016 | persian gulf syndrome | University of Utah | Terminated | No outcome recorded |
| Phase 2/3 | NCT00973908 Comparator | Apr 2010 → Apr 2012 | diarrheal disease | National Health Service, United Kingdom | Completed | No outcome recorded |
| Phase 2/3 | NCT00678613 Comparator | Jul 2007 → ? | cirrhosis of liver, infectious peritonitis | All India Institute of Medical Sciences | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03266913 Comparator | Aug → Oct 2017 | hyperbilirubinemia | Hormozgan University of Medical Sciences | Unknown | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT05160350 Comparator | Apr → Oct 2021 | epilepsy | Mazandaran University of Medical Sciences | Completed | No outcome recorded |
| Phase 4 | NCT01632462 Comparator | Sep 2012 → Dec 2014 | Crohn disease | Federico II University | Unknown | No outcome recorded |
| Phase 4 | NCT01178372 Comparator | Sep 2008 → Sep 2010 | hepatic encephalopathy | Govind Ballabh Pant Hospital | Unknown | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT07233382 Comparator | Dec 2025 → May 2026 overdue | necrotizing enterocolitis | Hayatabad Medical Complex | Not yet recruiting | No outcome recorded |
| — | NCT00683982 Comparator | Aug 2007 → May 2008 | Rotavirus infection, diarrheal disease | Centro Pediatrico Albina de Patino | Completed | No outcome recorded |
Evidence & citations 17 cited values
Every value below carries the sentence it was read from. 60 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VSL #3 | “VSL#3 is a commercial probiotic mixture consisting of eight probiotic lactic acid bacteria and Bifidobacteria including Lactobacillus acidophilus, Lactobacillus plantarum,...” NCT05608928 ↗35“The probiotic VSL #3 is easily available, cheap, effective and safe alternative or substitute for the existing therapeutic agents will be evaluated in this study for their...” NCT01479660 ↗ “This will be a double blind randomized placebo controlled study to determine the clinical efficacy of 12 weeks of oral probiotics (VSL#3) in patients with inflammatory bowel disease.” NCT01479660 ↗ “Patients will be randomised to receive either VSL#3 (450 billion lyophilized bacteria/sachet) twice daily for 4 weeks or a placebo powder containing starch but no bacteria.” NCT00418340 ↗ “The probiotic product VSL#3® comes in a powder (sachet) that is to be dissolved in half a glass of cold water before ingestion.” NCT01635192 ↗ “Patients will receive one VSL #3 sachets twice a day for the duration of the antibiotic course and for one week after.” NCT00973908 ↗ “Adults with IBS were randomized into an open label trial to receive the probiotic VSL#3 for 4 or 8 weeks.” PMID 35295488 ↗ Sep 2021 “Patients in this group will be given the probiotic VSL#3 2 packets BID for a total of 8 weeks.” NCT01032941 ↗ “VSL#3 probiotic 4 capsules orally daily or 1 sachet orally daily for up to 5 weeks” NCT01465802 ↗ “VSL#3 is a commercial probiotic mixture consisting of eight bacterial strains:” NCT05007470 ↗ “VSL #3 (probiotic mixture) is given to this group” NCT02011542 ↗ “The Probiotics used in this study will be VSL#3.” NCT00678613 ↗ |
| Known as | Align | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03399903 ↗ |
| Known as | B. infantis | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02286999 ↗ |
| Known as | Bifidobacterium animalis subsp. lactis HN019 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03386643 ↗ |
| Known as | Bifidobacterium longum subsp. infantis | “Herein we propose a novel phase I ascending dose trial of Bifidobacterium longum subsp. infantis (B. infantis) to identify the dose required to produce predominant gut...” PMID 27449926 ↗ Jul 2016 |
| Known as | EXE-346 Probiotic | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06949800 ↗ |
| Known as | Infloran | “Probiotic Infloran® Hard capsules” NCT07189390 ↗ |
| Known as | L. acidophilus La-5 | “In a randomized, double-blind trial, women received probiotic milk or placebo from 36 weeks of gestation up to 3 months postnatally while breast-feeding. The probiotic milk...” PMID 25782657 ↗ Aug 2015 |
| Known as | Lactobacillus crispatus probiotic | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07234227 ↗ |
| Known as | Lactobacillus Plantarum IS-10506 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05254249 ↗ |
| Known as | PIP toothbrush cleaner (Chrisal, Lommel, Belgium). | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02736994 ↗ |
| Known as | Probiotic | “Drug: Probiotic” NCT03266913 ↗ |
| Known as | Probiotic mix preparation | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00683982 ↗ |
| Known as | R-2487 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06297213 ↗ |
| Action | Inhibit | “the ability of a battery of Lactobacillus strains to inhibit the growth of S. agalactiae” NCT04165551 ↗ |
| Modality | Other / unclassified | “Probiotics, living bacteria taken orally” NCT00099723 ↗ |
| Route | Oral | “Probiotics, living bacteria taken orally” NCT00099723 ↗ |